A vaccine to help prevent MenB in adolescents and young adults
TRUMENBA is a vaccine to help prevent MenB (IMD caused by N. meningitidis serogroup B bacteria), for use in individuals aged 10 through 25 years.
How does it work?
TRUMENBA targets a protein found in over 95% of bacteria that cause Meningitis B. It works by helping the body make antibodies (the body’s natural defenses), which protect individuals against this disease. These antibodies kill the bacteria that cause Meningitis B.
If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them.
How is it given?
Your healthcare professional will inject TRUMENBA into the upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.
For routine immunization (standard schedule)
For those at increased risk of IMD*
* Individuals at increased risk of IMD may include persons with functional or anatomic asplenia, including sickle cell disease; persons with congenital complement, properdin, factor D or primary antibody deficiencies; persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab and individuals with HIV.